J&J Buys Scios: Will Natrecor Make Another Centocor?
Executive Summary
Johnson & Johnson will gain access to Scios' Phase II oral rheumatoid arthritis program through its proposed $2.4 bil. acquisition of the biotech company
You may also be interested in...
Seeking Turnaround, Myrexis Taps Two New Execs
Rather than pursue a sale, Myrexis will obtain revenue-generating drugs that it feels are underperforming in other hands. Until it chooses an asset to acquire, it will operate as a virtual company.
Natrecor Labeling Revised To Include Expanded Mortality Analysis
Johnson & Johnson/Scios' Natrecor (nesiritide) labeling has been revised to include an expanded analysis of the mortality rates seen in pivotal trials of the congestive heart failure agent
Natrecor Labeling Revised To Include Expanded Mortality Analysis
Johnson & Johnson/Scios' Natrecor (nesiritide) labeling has been revised to include an expanded analysis of the mortality rates seen in pivotal trials of the congestive heart failure agent